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The presence of immune memory at pathogen entry sites is a prerequisite for protection. 
Nevertheless, the mechanisms that warrant immunity at peripheral interfaces are not 
understood.  Here we show that the non-classical MHC class I molecule, the thymus 
leukemia antigen (TL), induced on dendritic cells together with CD8αα  on activated 
CD8αβ+T cells, mediates affinity-based selection of memory precursor cells. Furthermore, 
constitutive expression of TL on epithelial cells continues the selection of mature CD8αβ  
memory T cells. The TL-CD8αα-driven memory process is essential for the generation of 
memory CD8αβ  T cells in the intestine and leads to the accumulation of highly antigen 
sensitive CD8αβ  memory T cells that form the first line of defense at the largest entry port 
for pathogens.  
 
A hallmark of immune memory is that repeated infections are met with accelerated and 
enhanced protective immunity1.  Furthermore, unlike naïve T lymphocytes, or central memory T 
cells (TCM), that reside in lymphoid tissues, some antigen-experienced T cells gain the capacity to 
persist long-term as effector memory T cells (TEM) in non-lymphoid tissues, such as the intestine2-
5.  TCM cells, which respond with a robust clonal expansion, are effective at protecting against 
infections by pathogens that replicate systemically6, but they likely are inadequate to prevent 
transmission of viruses, including the human immunodeficiency virus (HIV), or intracellular 
bacteria, which penetrate across mucosal epithelia3, 7.  Effective resistance against transmission of 
such pathogens requires the presence of local antigen-specific TEM prior to re-challenge7.  
Therefore, strategies aimed at inducing a powerful protective immune response that also warrants 
the formation of pre-existing mucosal antigen-specific TEM are considered an essential goal of 
successful vaccinations.  
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Listeria monocytogenes (Lm), a Gram-positive intracellular pathogen of human and other 
mammals including mice, is a food borne pathogen, which upon ingestion and uptake by 
phagocytic cells, such as monocytes and dendritic cells (DC) disseminate from the intestine into 
the bloodstream and spread to various systemic tissues such as the liver8.  In humans, ingested Lm 
may cause listeriosis because of its ability to also infect non-phagocytic cells such as the intestinal 
epithelial cells (IEC) through interaction of the molecule internalin expressed by the Lm and 
human E-cadherin expressed on the baso-latheral pole of the enterocytes9. Mice, by contrast, when 
infected orally do not develop listeriosis due to the inability of Lm internalin to interact with 
mouse E-cadherin. Instead, mice clear the infection of ingested bacteria with an effective CD8-
dependent protective immune response, although bacteria that crossed the mucosal barrier can 
spread to the liver and other organs via the blood, as can occur in humans8. These observations 
have important implications for immunization strategies and indicate that the presence of local pre-
existing mucosal immunity might be key for the induction of effective protective immunity against 
food borne pathogens.  Despite this however, most of the current knowledge of immune memory 
has been gained from model systems that use systemic immunization routes and memory 
generation in lymphoid tissues. Although such pre-existing immunity might be highly effective to 
combat pathogens that enter the body systemically, it is most likely inadequate to prevent entry 
and systemic spreading of pathogens, which invade via the mucosal route of the intestine. Because 
mice can be infected by the oral route similarly to humans and because of the protective 
endogenous mucosal CD8-mediated immune response that is generated in mice in response to 
ingested bacteria, together with the emergence of genetically manipulated avirulent attenuated wild 
type- and recombinant (ActA-) Lm strains as important vectors for vaccinations8, 10, 11, 
immunizations of mice with Lm introduced via the oral route represent an optimal approach to 
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examine mechanisms and conditions that lead to the generation of effective pre-existing mucosal 
immune memory.  
 We showed previously that CD8 homodimers (CD8αα), induced on activated CD8αβ T 
cells, which maintain expression of CD8αβ, mark those primary effector cells that preferentially 
differentiate to memory cells12. In mice, memory CD8αβ T cells that co-express CD8αα are 
greatly enriched in the epithelium of the intestine13.  In that same location, the high affinity ligand 
for CD8αα14, a non-classical, nonpolymorphic MHC class I molecule, known as the thymus 
leukemia antigen but hereafter called TL, is constitutively expressed on the adjacent epithelial 
cells15, 16.  This suggests a role for epithelial TL in the accumulation of mucosal CD8αα+CD8αβ 
memory T cells, however the mechanisms that drive the CD8αα-dependent generation of mucosal 
immune memory remained unknown.  
Using the oral Lm infection model to elicit a CD8-driven protective immune response 
initiated at the mucosal entry site, we define here a novel, affinity-based selection mechanism 
controlled by TL expression, induced on antigen presenting cells (APC), that leads to the survival 
and differentiation of high affinity, CD8αα+CD8αβ memory precursor cells.  Furthermore, the 
data also indicate that the constitutive expression of TL on the epithelium of the intestine continues 
to impose selection pressure, which contributes to the affinity maturation of the resident mucosal 
CD8αβ TEM. 
 
RESULTS 
TL is not required for the formation of memory CD8αβ+T cells. 
Considering the class I-like antigen presenting molecules in the mouse genome, TL is 
distinguished because it has a particularly high affinity for CD8αα, due to unique amino acids 
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substitutions at three positions in the membrane proximal α3 domain17.  To assess if TL, the most 
likely physiologic ligand for CD8αα in vivo12, also plays a role in the generation of CD8αβ 
effector memory cells, we analyzed CD8αβ T cell memory differentiation in TL gene (T3b) knock 
out (TL-/-) mice18.  The absence of TL did not impair, but rather enhanced, the generation of OVA-
specific CD8αβ memory T cells in the spleen of TL-/- mice infected orally with Lm bacteria 
expressing OVA antigen (Lm-OVA) (Fig. 1a).  A similar effect was observed in the epithelium of 
the intestine when intraepithelial lymphocytes (IEL) were analyzed (Fig. 1a).  Likewise, naïve 
OVA peptide (OVAp) and H-2Kb specific monoclonal TCR transgenic OT-I T cells transferred to 
WT or TL-/- recipient mice that were subsequently orally infected with Lm-OVA also generated 
more OT-I TCR transgenic memory T cells in the absence of TL expression (Fig. 1b).  These 
observations are consistent with previous published data using single chain MHC class I transgenic 
mice on a β2m deficient background, which also indicated that in the absence of TL, normal or 
slightly enhanced memory formed in response to a viral infection19. All together, the data show 
that, whereas CD8αα promotes memory differentiation of CD8αβ+ effector T cells12, its high-
affinity ligand TL, appears to inhibit this process. 
 
TL negatively affects memory generation of CD8αβ +effector cells. 
 TL has a restricted pattern of expression20 that includes induction on antigen presenting cells 
(APC), such as DC, in addition to expression on epithelial cells12.  The increase in memory 
CD8αβ+ T cells seen in the absence of TL in TL-/- mice suggests that, under normal conditions, TL 
expression on subsets of priming DC might negatively influence survival or differentiation of 
CD8αβ memory precursor cells.  To test this possibility, we analyzed the effect of constitutive TL 
expression during priming using TL transgenic (TL-Tg) mice, which express an allelic form of TL 
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(T18d) under the control of the promoter from the MHC class I molecule, H-2Dd.  In contrast to the 
outcome in TL-/- hosts, transferred OT-I T cells which were primed in vivo in TL-Tg recipient mice 
that were orally infected with Lm-OVA failed to generate or sustain immune memory, either 
locally in the intestine or systemically, including in the spleen and liver (Fig. 1c and 
Supplementary Fig. 1).  Moreover, OT-I T cells primed systemically in vivo using TL-Tg OVAp-
loaded bone marrow (BM) DC that were adoptively transferred failed to generate memory cells in 
the spleen of WT hosts (Fig. 1d).  Similarly, OT-I cells initially primed in vitro by TL-Tg OVAp-
expressing APC, did not generate memory cells following adoptive transfer (Fig. 1d).  These data 
indicate that TL expression on APC interferes with the survival and memory programming of 
primary CD8αβ+ effector cells. 
Under steady state conditions resting spleen DC normally do not express detectable levels of 
TL surface protein, although some induce it upon activation12.  However, an analysis of different 
DC subsets indicated that in contrast to spleen DC, a subset of mesenteric lymph node (mLN) DC 
constitutively express a low level of TL.  This TL+ subset has the phenotype of mature migratory 
DC (MHC class II high/CD11c+ and CD103+CCR7+) (Supplementary Fig. 2a), which is also 
typical of those DC that drive retinoic acid (RA)-based induction of gut homing receptors on the T 
cells they prime21, (Fig. 1e and Supplementary Fig. 2b).  The expression of TL on these mucosal 
DC was further upregulated during priming, and greatly enhanced in response to innate immune 
stimuli such as CpG oligodeoxynucleotides (Fig. 1f).  These observations indicate that naïve T 
cells responding in vivo to gut-derived antigens are primed in the context of TL, expressed by the 
migratory DC and greatly upregulated under inflammatory conditions. 
 
TL induces Fas-mediated death of activated CD8αβ+T cells. 
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Although TL displays structural characteristics of MHC class I molecules, it does not function 
as a typical antigen-presenting molecule.  The narrow distance between the α helices that form the 
boundaries of the antigen binding groove will not permit TL peptide binding and presentation22 
and therefore TL fails to engage with the αβ TCR.  Nevertheless the high degree of conserved 
sequence in the α3 domain allows TL to interact with the CD8αβ co-receptor, despite the 
exclusion of TL from the TCR activation complex14.  A similar interaction of soluble HLA class I 
molecules with CD8αβ TCR co-receptor, separately from TCR ligation, was previously shown to 
lead to Fas-FasL-induced cell death23-26. To investigate if the TL interaction with CD8αβ on 
activated T cells might also lead to cell death, we measured the survival of naïve and antigen 
stimulated CD8αβ+ cells in the presence of constitutive TL expression in TL-Tg hosts.  Whereas 
naïve donor cells survived similarly in WT or TL-Tg mice, activated CD8αβ+ OT-I cells survived 
only in WT but not in TL-Tg hosts (Fig. 2a), supporting the notion that TL-induced cell death 
(TICD) targets activated CD8αβ+ T cells.  Activated Fas-deficientlpr/lpr CD8αβ+ donor T cells, 
however, were not deleted in TL-Tg recipient mice, providing evidence that, similar to the reported 
death by soluble HLA-G23, 24, TICD also involves the Fas/FasL-mediated death pathway (Fig. 2b). 
 
Activation-induced CD8αα  rescues CD8αβ  effector T cells. 
In contrast to CD8αβ, CD8αα does not function as a TCR co-receptor and similar to TL, 
CD8αα also does not engage in the TCR activation complex27, 28.  However, whereas TL induces 
death of activated CD8αβ+ T cells, CD8αα, which exhibits a stronger affinity for TL compared to 
CD8αβ14, promotes the survival of CD8αβ effector cells12, suggesting that activation-induced 
CD8αα might interfere with TICD.  To test this, we compared the survival and memory 
differentiation of CD8αβ effector T cells in the absence or presence of CD8αα.  Due to a deletion 
 8 
of CD8α enhancer region I (E8I-/-)29, OT-I CD8αβ donor cells on the E8I-/- background (E8I-/-OT-I 
CD8αβ+) do not induce detectable levels of activation-dependent CD8αα12.  When analyzed in 
vitro, E8I-/-OT-I CD8αβ T cells primed by OVA-loaded mLN DC, which constitutively express TL 
(Fig. 1e), showed increased activation induced death compared to their counterparts primed by 
spleen DC (Fig. 3a).  However, the increase in cell death induced by these mucosal APC was not 
observed when mLN and spleen DC isolated from TL-/- mice were compared (Fig. 3a). 
Furthermore, similar to our previous published results showing impaired spleen memory 
generation by E8I-/- CD8αβ T cells in response to a systemic immunization with Lymphocytic 
Choriomeningitis virus (LCMV)12, E8I-/-OT-I CD8αβ donor cells primed in vivo with Lm-OVA 
via the oral route, also failed to generate detectable memory cells in the spleen or the intestine of 
WT recipient mice (Fig. 3b). In contrast, in another study by Chandele et al., using the same 
systemic LCMV immunization approach, E8I-/- CD8αβ T cells did generate systemic memory30.  
However in that case, a drastic downregulation of CD8αβ was noticed during the initial priming 
phase, which was not seen on either WT CD8αβ T cells or the LCMV primed E8I-/- CD8 T cells in 
our published study12. It is possible that stronger activation conditions in the Chandele study might 
have caused the downregulation of CD8αβ, which likely resulted in similar effects on survival as 
mediated by activation-induced CD8αα on normal WT CD8αβ T cells.  To test this, we analyzed 
the memory response of E8I-/-OT-I CD8αβ+ T cells primed systemically with Lm-OVA introduced 
intravenously (i.v.), which induces a much more potent immune response as compared to the oral 
route8. In contrast to the oral immunization, systemic priming of the E8I-/-OT-I CD8αβ+ T cells 
with Lm-OVA resulted in a clear memory response in the spleen and in the intestine comparable to 
that of WT OT-I cells  (Fig. 3c).  Furthermore, similar to the Chandele study30, a drastic 
downregulation of CD8αβ was noticed during the potent priming of E8I-/-OT-I CD8αβ+ T cells 
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activated via the i.v. route, whereas, such downregulation was not observed when E8I-/-OT-I 
CD8αβ+ T cells were primed via the oral route (Fig. 3d). Although the activation-induced 
downregulation of CD8αβ could explain the survival of the E8I-/-OT-I CD8αβ+ T cells during the 
systemic priming, it does not explain the longterm survival of these cells in the intestine where TL 
is constitutively expressed on the IEC. To further investigate this, we analyzed the CD8αβ 
expression of the E8I-/-OT-I CD8αβ+ memory T cell subsets in the spleen and the intestine.  
Interestingly, whereas E8I-/-OT-I CD8αβ+ memory cells in the periphery expressed normal levels of 
CD8αβ, memory E8I-/-OT-I CD8αβ+ IEL that persist in the presence of TL expressed much 
reduced levels of CD8αβ (Fig. 3e). These results indicate that the mechanism of TICD 
continuously and selectively shapes the repertoire of the memory cells that accumulate at the 
mucosal site of the intestine.  In support of this, in the absence of TL expression in the intestine of 
TL-/- hosts, similar to the systemic priming, there was no difference in the efficiency of memory 
formation in the spleen or the intestine when WT OT-I or E8I-/-OT-I CD8αβ+ T cells were primed 
via the oral route (Fig. 3f).  Furthermore, there was also no selective accumulation of CD8αα 
expressing WT OT-I CD8αβ IEL in the TL-/- hosts, indicating that TL on the epithelial cells in the 
intestine imposes a selective pressure to promote the local accumulation of CD8αα-expressing 
effector memory T cells (Fig. 3g). These results indicate that the requirement for activation-
induced CD8αα on primary effector cells is in part determined by the presence of TL.  The data 
are consistent with a role for activation-induced CD8αα in sequestering TL ligand away from the 
CD8αβ co-receptor, thereby avoiding TICD of the CD8αβ+ primary effector T cells. 
 
CD8αα  expression is linked to the intensity of TCR activation. 
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Due to the relatively high affinity interaction of CD8αα with TL, activation-induced 
expression of CD8αα can be distinguished from CD8αβ co-receptor expression using TL 
tetramers12.  Activated CD8αβ T cells do not all induce CD8αα to the same extent, and using TL 
tetramers a variegated expression pattern of high (CD8ααhi) and low (CD8ααlo/-) expression is 
typically observed.  Together with the fact that the initial induction of CD8αα requires TCR 
stimulation, this suggests that there might be a close link between the intensity of TCR activation 
and the degree of CD8αα induction.  In support of this, TL tetramer staining of polyclonal 
CD8αβ+ WT T lymphocytes activated in vitro with variable concentrations of soluble α-CD3 and 
α-CD28 antibodies showed graded increase in CD8αα expression with higher concentrations of α-
CD3/CD28 mAbs (Fig. 4a).  Furthermore, OT-I T cells stimulated with different altered peptide 
ligands (APL) that bind equally well to the Kb class I molecule as the original OT-I ligand, 
SIINFEKL (N4), but which have different antigenic potencies31, also showed a tight association 
between the level of CD8αα induction and the degree of TCR activation.  Therefore the high 
affinity N4 ligand induced the highest amounts of CD8αα expression compared to the lower-
affinity altered peptide ligands (Fig. 4b).  Similar results of affinity-based induction of CD8αα 
were obtained in vivo when mice were analyzed that were infected orally with Lm-OVA after they 
received either a high- or a low-precursor frequency of naïve donor OT-I cells, which because of 
antigenic competition will model a low or high antigen dose, respectively (Fig. 4c).  Additionally, 
we analyzed recipient mice adoptively transferred with equal amounts of OT-I precursor cells, but 
orally infected with bacteria expressing either the low-affinity Q4 (Lm-Q4)- or the high-affinity 
N4 (Lm-N4)-antigen.  Mice receiving higher affinity N4 as compared to Q4 antigen generated 
more CD8αα-expressing CD8αβ T cells (Fig. 4d).  In each of these approaches, the results 
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consistently indicated that the level of CD8αα induction represents a sensitive measurement for 
the intensity of the signal strength received through the activated TCR.  
Similar to activation-induced CD8αα; IL-7 receptor (IL-7Rα) expression also has been 
proposed as a marker for memory precursor cells32.  However, in contrast to CD8αα, IL-7R 
expression did not correlate with TCR activation, and instead, IL-7R was constitutively expressed 
on naïve cells and initially down regulated during activation at the time when CD8αα is first up 
regulated (Supplementary Fig. 3a).  The reciprocal expression of CD8αα and IL-7R suggests 
different roles for these molecules in memory programming and/or survival.  Consistent with this, 
a mutation in the cytoplasmic IL-7Rα Y449XXM motif (IL-7Rα449F), known to impair the long-
term survival of IL-7R-dependent CD8 memory T cells33, did not interfere with the induction of 
CD8αα or the survival and generation of OT-I/ IL-7Rα449F memory T cells in response to an oral 
immunization with Lm-OVA (Supplementary Fig. 3b).  These data indicate that the affinity-
based selective programming of memory precursor cells does not depend on IL-7R signals. 
Overall, the data indicate that in addition to being a memory precursor marker12, 
CD8αα expression also reports on the affinity/avidity of the antigen signal received by activated 
CD8αβ primary effector cells.  The affinity-based induction of CD8αα, together with the ability of 
CD8αα to sequester TL and avoid TICD therefore represents a mechanism to selectively preserve 
the most avid CD8αβ primary effector cells as part of the memory precursor pool.  
 
CD8αα  expression marks high affinity CD8αβ  T cells in humans. 
Previous evidence indicated that the mouse TL tetramers also detect expression of human 
CD8αα homodimers12, 17.  Consistent with activation-induced expression of CD8αα, human 
CD8αβ effector cells also stained with TL tetramers, whereas naïve T cells did not (Fig. 5a).  TL 
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tetramer staining could be blocked with an anti-human CD8α antibody, but not with an anti-CD8β 
antibody, confirming the specificity of the TL tetramer for human CD8αα (Fig. 5b and 
Supplementary Fig. 4). Furthermore, the subset of immuno-dominant, high affinity, CMV-pp65-
specific CD8αβ T cells34, isolated from Cytomegalovirus (CMV)-sero-positive individuals, stained 
almost exclusively with TL tetramer, which could be blocked with anti-CD8α (Fig. 5c), indicating 
that CD8αα expression on human CD8αβ effector T cells also is associated with high affinity 
effector cells. 
 
Retinoic acid and TGF-β  promote affinity-based accumulation of CD8αα+CD8αβ  T 
cells. 
CD8αα-expressing CD8αβ T cells are highly enriched in the epithelium of the intestine, 
suggesting that a selective process based on CD8αα expression might drive this localized 
accumulation.  Consistent with this, when primed in vitro CD8αα induction was stronger using 
mLN DC compared to spleen DC (Fig. 6a,b).  In the presence of exogenous RA, normally released 
by mLN DC during priming21, spleen DC also mediated strong induction of CD8αα on the OT-I T 
cells they primed (Fig. 6a,b).  Whereas a retinoic acid receptor (RAR) inhibitor reduced CD8αα 
expression on T cells primed by mLN DC (Fig. 6a).  Likewise, TGF-β known to be an important 
modulator of mucosal T cell differentiation also increased CD8αα induction on activated CD8αβ 
primary effector cells (Fig. 6c). Both, RA- and TGF-β-mediated enhanced induction of CD8αα 
were observed, however, only under strong antigen activation conditions, suggesting that they 
influence CD8 effector differentiation by further promoting the selective marking of high affinity 
effector cells by CD8αα (Fig. 6b, c). 
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The constitutive and enhanced expression of TL on the mucosal migratory DC known to 
release RA and TGF-β (Fig. 1e, f), together with the increased CD8αα induction on high affinity 
effectors in the presence of RA as well as TGF-β, indicate that the selective rescue of high affinity 
memory precursor cells is geared toward effector cells that home to the gut.  In agreement with 
this, CD8αα-expressing OT-I cells were first detectable at mucosal induction sites, such as the 
mLN and Peyer’s patches, early after oral antigen exposure (Fig. 6d) and gradually accumulated 
during the contraction and memory phase within the pool of αEβ7 integrin (CD103+) TEM in the gut 
epithelium, but not in the CD103- memory cells that persist systemically (Fig. 6e). 
 
Constitutive TL on epithelial cells continues to select mature CD8αβ  TEM. 
The constitutive TL expression on intestinal epithelial cells15, 16, suggests that TL might 
continuously shape the resident mucosal memory CD8αβ+ T cell population even after 
rechallenge.  To investigate this, we examined the fate of primary and secondary CD8ααhi- or 
CD8ααlo/--CD8αβ+ effector T cells in vivo.  OT-I cells initially primed in vitro in the absence of 
TL, using TL negative APC, were sorted into CD8ααhi- and CD8ααlo/--primary effector T cells 
and adoptively transferred to WT recipient mice.  Both subsets of primary effector cells displayed 
a similar short term homing capacity (Supplementary Fig. 5a), and both effector T cell types 
responded alike when tested in vitro for IFNγ production (Supplementary Fig. 5b) or in vivo for 
cytotoxicity (Supplementary Fig. 5c).  However, in response to an oral re-challenge with Lm-
OVA, primary memory OT-I T cells derived from the CD8ααhi precursors expanded in the spleen 
and in the intestine of the WT recipient mice, whereas memory cells from the CD8ααlo/- effector 
pool were only detectable in the host spleen, but not in the intestine (Fig. 7a).  These data indicate 
that only CD8ααhi primary memory cells can persist long-term as mucosal TEM in proximity of TL 
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constitutively expressed on the epithelial cells.  Upon re-challenge, activated memory cells in 
lymphoid tissues expand and migrate as secondary effector cells to non-lymphoid tissues, such as 
the epithelium of the gut35.  In agreement with this, comparable numbers of effector cells derived 
from either CD8ααhi or CD8ααlo/-primary effector OT-I cells were present in the intestine 5 days 
after recall (Fig. 7b).  Nevertheless, when analyzed 45 days later, progeny of CD8ααhi effector 
cells were present as secondary memory cells in both the spleen and the intestine, whereas the 
CD8ααlo/- secondary effector cells did not remain as secondary TEM in the intestine (Fig. 7c).  In 
contrast, in vitro primed CD8ααlo/-CD8αβ+ OT-I effector cells accumulated efficiently as TEM 
within the gut epithelium of TL-/- recipient mice (Fig. 7d), indicating that the constitutive 
expression of TL continues to mediate selective pressure that prevents the accumulation of 
CD8ααlo/- primary and secondary effector cells as mucosal TEM.  These results also specify that 
CD8ααlo/-effector cells are not intrinsically incapable of converting to mucosal TEM, but that under 
normal physiological conditions, only CD8ααhi primary effector cells form long-lived mucosal 
TEM in proximity to TL constitutively expressed on the epithelial cells. 
 
Constitutive TL mediates affinity maturation of mucosal memory CD8αβ  T cells. 
 A recent study, using low-affinity APL for in vivo priming, suggested that affinity maturation 
of memory T cells was the result of enhanced expansion and delayed contraction of the high 
affinity responding effector cells31.  Our results here suggest that, in addition, the TL-mediated 
selective survival of CD8αα-expressing high affinity memory cells might also contribute to ensure 
affinity maturation of memory populations at the mucosal border.  To provide direct evidence for 
this, we used the same APL approach31 to examine memory generation in vivo in the presence or 
absence of TL.  Naïve OT-I cells were adoptively transferred to either WT or TL-/- recipient mice 
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that were subsequently orally infected with bacteria expressing the low affinity APL, Q4 (Lm-Q4), 
which does not effectively induce CD8αα on primed OT-I effector cells (Fig. 4d). Fewer OT-I 
effector cells were detectable in the blood of WT mice compared to TL-/- animals when analyzed 7 
days after oral immunization with Lm-Q4 (Fig. 7e), suggesting that TL induced on the priming 
mucosal APC controls in part the expansion of the primary effector pool. In the intestine, where 
TL is constitutively expressed by the IEC, the selective impact of TL was even more pronounced 
and OT-I memory IEL generated in response to the low affinity peptide Q4 are barely detectable in 
WT animals whereas they were readily present in the TL-/- mice (Fig. 7f). These results indicate 
that the continuous expression of TL on the epithelium of the intestine selectively eliminates low 
affinity cells from the pool of mature mucosal TEM. Together with the increase in mucosal memory 
in the TL-/- mice, also the systemic memory pool was increased (Fig. 7f), suggesting that in 
addition to the TL-mediated affinity selection of mature memory cells in the intestine, TL induced 
on the mucosal APC during priming might already provide a first affinity- selection step by 
eliminating low affinity/avidity primary effector cells form the memory precursor pool.  To further 
test this, we immunized WT or TL-/- recipient mice with Lm-Q4 via the i.v. route. Under these 
conditions, TL expression during priming had only a minimal effect on the effector- or memory 
phase of peripheral T cells, which was comparable between the TL-/- and WT recipient mice (Figs. 
7g and 7h).  In sharp contrast however, the accumulation of TEM at the mucosal site, where TL is 
constitutively expressed, remained under the TL selective pressure (Fig. 7h). These results 
indicated that T cells primed at the mucosal priming site undergo an initial selection step mediated 
by TL induced on the migratory DC, whereas the constitutive expression of TL on the mucosal 
epithelium provides for additional and constant selection pressure that drives continuous affinity 
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maturation of the mature memory pool that accumulates longterm at the mucosal interface of the 
intestine. 
To evaluate the importance of pre-existing TL-CD8αα-selected mucosal memory T cells 
residing at this entry port, we examined the resistance against an oral infection with Lm in mice 
with or without affinity-selected memory cells.  To this end, mice transferred with either WT or 
E8I-/- OT-I cells were orally immunized with an attenuated strain of Lm-OVA (ActA- Lm-OVA) 
(109 cfu).  The mice were subsequently re-challenged orally with a higher dose (1010 cfu) of WT 
Lm-OVA and analyzed for systemic spreading of the pathogen.  In contrast to the efficient 
resistance observed in mice which received the WT OT-I precursor cells, which generated memory 
cells in the intestine and elsewhere, pre-immunized mice that initially received the E8I-/-OT-I 
precursor cells failed to generate affinity selected memory and they showed significantly less 
resistance to prevent systemic spreading of the orally introduced pathogen (Fig. 7i).  These results 
underscore the importance of the selective immune memory differentiation process as a critical 
mechanism for the efficient generation of pre-existing immunity at critical mucosal interfaces that 
form the main entry sites for invading pathogens. 
 
DISCUSSION 
The data presented here define a fundamentally new concept for our understanding of immune 
memory differentiation and in particular mucosal immunity.  The data demonstrate that an affinity-
based selective process operates in vivo that preserves the optimal effector cells to become long-
lived memory T cells that form pre-existing and heightened protective immunity. This mechanism 
is especially geared to generate high affinity TEM that line the mucosal barrier of the intestine, 
where most pathogens enter the body. 
 17 
The results also demonstrate a functional role TL, a non-classical MHC class I-like molecule, 
in mediating TICD of CD8αβ effector T cells that fail to induce CD8αα.  Because TL is a much 
stronger ligand for CD8αα as compared to CD8αβ, CD8αα likely can sequester TL away from 
CD8αβ and prevent TICD (Supplementary Fig. 6).  The induction of CD8αα is directly linked to 
the degree of TCR signal strength, which leads to the selective survival of the most avid effector 
cells to become memory T cells.  The constitutive expression of TL on the epithelial cells in the 
intestine continues selective pressure which mediates affinity maturation of the mucosal TEM 
population in response to repeated re-challenges (Supplementary Fig. 6).  
The data here, using the Lm model are consistent with our previously published study using 
the LCMV model system, which also indicated a critical role for activation-induced CD8αα in the 
generation of CD8αβ memory T cells, Nevertheless, two subsequent studies challenged this 
conclusion and provided evidence that under certain conditions CD8αβ+ E8I-/- memory T cells 
could also be generated in a CD8αα-independent fashion30, 36. In those two studies however and 
similar to what we observed here using Lm immunizations via the iv route, there was a pronounced 
down regulation of CD8αβ expression during the priming of the E8I-/- CD8αβ T cells, which was 
not observed in our previous study using the LCMV system or during oral immunizations using the 
Lm system as shown here. The fact that in the absence of CD8αβ downregulation in both of those 
cases, E8I-/- CD8αβ T cells failed to accumulate as memory cells, indicates that strong activation 
signals which result in down regulation of CD8αβ co-receptor on the E8I-/-mutant cells may rescue 
CD8αβ memory precursor cells similarly to the biological activity of activation-induced CD8αα 
on normal WT CD8αβ effector cells.   
Although, a sequence-based homologue for TL in humans has not been identified, TL and the 
non-classical MHC class I molecule, HLA-G, display striking similarities, including their 
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restricted pattern of expression, the limited antigen presentation capacity, the relative strong 
affinity for CD8αα  compared to CD8αβ and the ability to induce Fas-FasL cell death of activated 
CD8αβ T cells25, 37, 38.  These parallels suggest that, similar to other non-classical MHC/HLA 
pairs, TL and HLA-G might represent functional homologues of each other, and they further 
suggest that an affinity-based selective memory differentiation program likely operates in humans 
as well. Consistent with this, we showed that activated but not naïve human CD8αβ T cells co-
express CD8αα, and CD8αα expression also coincided with the high affinity CMVpp65-specific 
CD8αβ effector T cells.  In addition, a recent study indicated that the endogenous protective 
immune response against HIV was characterized by a CD8αα-expressing CD8αβ subpopulation 
that exhibited strong antiviral activity39 and high-avidity HIV-specific CD8+ T cell clonotypes 
were largely preserved in patients who control viremia, but not in progressive chronic HIV 
infections. All together, these observations suggest that CD8αα induction on human CD8αβ T 
cells is also an activation-induced and affinity-based process that marks the avid effector cells. 
 Most infections, including Lm but also many viral infections such as HIV and SIV infections, 
are acquired across mucosal barriers, and several studies have demonstrated that CD8+ CTL 
responses play a crucial role in the initial containment and early control of pathogen replication40-
44. Although such responses may be unable to provide sterilizing protection, they can control the 
pathogen load and delay or even prevent spreading and onset of disease, as well as reduce the 
potential for secondary transmission. Therefore, the finding that an endogenous TCR quality-based 
mechanism may select for the most avid effector cells to form immune memory cells that have the 
capacity to reside longterm at mucosal interfaces, has significant implications for the design of 
new and improved strategies to induce effective pre-existing protective immunity, not only 
systemically but also locally at the major and most vulnerable entry sites for pathogens.  
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METHODS 
Mice. C57BL/6 CD45.2 (Ly5.2), referred to as WT, and CD45.1 (B6.SJL, Ly5.1) congenic, 
B6.MRL-Faslpr/J and B6.Smn.C3-FasLgld/J mice were purchased from The Jackson Laboratory 
(Bar Harbor, ME, USA).  OT-I TCR-transgenic mice were crossed onto the Ly5.1 congenic 
background.  Additionally, E8I-/-, IL-7Rα449F, and TL-Tg mice were crossed to OT-I mice.  TL-Tg 
mice were generated by forced expression of the T18d gene under the Dd promoter and backcrossed 
to the C57BL/6 background for more than 12 generations.  TL-/- mice were generated by deletion 
of the T3b gene in the C57BL/6 background.  Mice were maintained by breeding under specific 
pathogen-free conditions in the animal facility of the La Jolla Institute for Allergy & Immunology. 
Unless otherwise noted, mice were maintained under specific pathogen-free conditions.  Sentinel 
mice from the RAG1-/- colony were tested to be negative for Helicobacter spp. and Citrobacter 
rodentium.  Animal care and experimentation were consistent with the NIH guidelines and were 
approved by the Institutional Animal Care and Use Committee of the La Jolla Institute for Allergy 
and Immunology. 
 
T cell isolation, cell sorting, CFSE labeling and adoptive transfer.  CD8+ OT-I cells were 
purified by magnetic negative selection using the MACS CD8α+ T cell isolation kit according to 
the manufacturer’s protocol (Miltenyi Biotec).  CD44low cells were sorted as naïve CD8 OT-I cells 
by FACSAria (Becton Dickinson).  In some cases, sorted cells were CFSE-labeled.  OT-I cells 
were resuspended at a concentration of 10 × 106 cells/ml in PBS and CFSE was added to a final 
concentration of 5 µM (Invitrogen).  After 10 min of incubation at 37°C, labeling was quenched 
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with ice-cold DMEM medium with 10% FCS.  Cells were washed with PBS three times and 
intravenously injected into the recipient mice.  
 
DC isolation and activation. Pooled spleens or MLNs were cut into small pieces and digested 
with collagenase D (Roche) at room temperature for 30 min and EDTA (5 mM in final 
concentration) was added for the last 5 min.  Digested tissues were further homogenized and then 
enriched for CD11c+ DC by positive selection using a MACS cell separation (Miltenyi Biotec).  
For DC activation in vitro, freshly isolated spleen DC were cultured with 1 mM CpG DNA (1826, 
IDT) for 1 day and analyzed for TL expression by using anti-TL antibody (HD168). 
 
In vitro T cell stimulation culture. For total splenocyte culture, 5 × 105 total splenocytes were 
cultured in 96-well plates in the presence of anti-CD3 and anti-CD28 antibodies.  For artificial 
APC/OT-I cultures, either the transfected adherent fibroblast cell line (MEC.B7) expressing the 
costimulatory molecule B7.1, or the OVA-expressing cell line (APC, MEC.B7.SigOVA) having 
the OVA-derived, H-2Kb-restricted peptide epitope OVA257-264 (SIINFEKL), along with B7.1, 
were used.  Irradiated APCs were cultured at 150,000 cells per well in 24-well plates overnight to 
establish a single layer.  Naïve OT-I cells (5 × 105) were added to the monolayer of APCs in 2 ml 
of medium. The TL expressing APC (APC-TL) were generated by transfection of 
MEC.B7.SigOVA cells with a plasmid expressing T18d gene.  TL expression was confirmed by 
staining with a TL-specific antibody (HD168).  For DC/OT-I culture, purified DC were incubated 
with 1 nM SIINFEKL for 2 h and then washed.  2 × 105 CFSE-labeled naïve OT-I cells were 
cultured with 4 × 104 peptide-pulsed DC, with or without 100 nM all-trans RA (Sigma), in 96-well 
plates for 3-4 d.  RA receptor antagonist LE135 (TOCRIS bioscience) was used for some cultures. 
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Bone marrow-derived DC immunization. Bone marrow was flushed from the tibia and femurs 
of 8-10-week-old mice and red blood cells were lysed.  Bone marrow cells were plated at 5 × 105 
cells/ml in complete IMDM with 20 ng/ml rmGM-CSF (Kyowa-Hakko Kirin California).  Fresh 
media containing rmGM-CSF were added on day 3 and half of the media was gently replaced on 
day 6.  100 ng/ml LPS (Sigma) was added on day 6 for 1 d to induce DC maturation and then 1 
mM SIINFEKL was added to the culture 2 h before collecting cells.  After extensive washing, 5 × 
105 DC were injected i.v. in mice, which had previously received naïve OT-I cells 1 d earlier. 
 
qRT-PCR. RNA from the FACS-sorted DC were extracted with TRIZol (Invitrogen) and 
complementary DNA (cDNA) were synthesized using the iScript cDNA Synthesis kit (Bio-Rad). 
Real time RT-PCR was performed with the Roche 480 real-time PCR System. Values were 
normalized by the amount of L32 in each sample. The primers for qPCR are as following: TL-
forward 5’-TGT ATG GCT GTG AGG TGG AG-3’, TL-reverse 5’-GCT CCC ACT TGC TTC 
TGG T-3’; L32-forward 5’-GAA ACT GGC GGA AAC CCA-3’, L32-reverse 5’-GGA TCT GGC 
CCT TGA ACC TT-3’. 
 
Bacterial infection and bacterial counts in organs. ActA- Lm-OVA for immunization were 
prepared from cultures in brain heart infusion broth.  Lm-N4OVA and Lm-Q4OVA strains stably 
express chicken ovalbumin (AA134–387) containing either the native ligand SIINFEKL257–264 (N4) or 
the altered peptide ligand SIIQFEKL (Q4).  Bacteria were washed and resuspended in Hanks' 
balanced salt solution (HBSS) prior to oral infection by gavage.  Bacterial injection stocks were 
plated to confirm the CFU.  To count the bacteria in organs, livers were sterilely dissected, 
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homogenized and lysed with 0.1% Triton X-100.  Serial dilutions were plated onto BHI plates and 
bacterial colonies were counted 24 h after incubation at 37 °C. 
 
IEL preparation. In brief, small intestines were removed and separated from Peyer's patches. 
They were cut longitudinally and then into 0.5 cm pieces.  The pieces were shaken for 40 min in 
Mg2+-free, Ca2+-free HBSS supplemented with 1 mM dithiothreitol and 5% FCS.  Cells were 
collected from the washes and passed over a discontinuous 40/70% Percoll (Pharmacia Biotech) 
gradient at 900 g for 20 min. IEL were then isolated from the Percoll-gradient interface and washed 
free of Percoll. 
 
Immunofluorescence staining and flow cytometry. For mouse samples, a standard surface 
staining protocol included pre-incubated with anti-CD16/CD32 Fc-receptor antibody (2.4G2) to 
block Fc-antibody binding.  Then, cells were stained in cold PBS containing 0.5% FBS and 0.05% 
sodium azide with the relevant labeled antibodies and tetramers. The following antibodies were 
used: CD8α (clone 53.6.7), CD8β (clone 53-5.8), CD44 (clone IM7), CD45.1 (clone A20), 
CD45.2 (clone 104), CD103 (clone M290), CD127 (IL-7Rα , clone A7R34), and IFN-γ (clone 
XMG1. 2).  All primary antibodies were directly conjugated to fluorophores (BD Biosciences or 
eBioscience). CD8αα was detected with PE-labeled TL-tetramers. OVA-specific CD8 T cells 
were detected with PE-labeled Kb/ OVA257-264 tetramers. For intracellular staining of IFNγ, 
splenocytes or IEL were stimulated with OVA257-264 (5 µg/ml) for 5 h in the presence of brefeldin 
A at 37°C.  After surface staining, intracellular cytokine staining for IFNγ was performed using a 
Cytofix/Cytoperm Kit (BD Biosciences), according to the manufacturer’s directions.  For detection 
of cell apoptosis and death, cells were stained with Annexin V-APC (BD Biosciences) using the 
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manufacturer’s protocol and cells were analyzed immediately after staining.  For human samples, 
peripheral blood samples were obtained from healthy volunteers (26-78 years old). Informed 
written consent was obtained from all participants and the blood collection was approved by the 
ethics committee of the Innsbruck Medical University.  Isolation of peripheral blood mononuclear 
cells (PBMC) was performed by density gradient centrifugation using Ficoll-Hypaque (Amersham 
Biosciences).  Immunofluorescence surface staining of PBMC was performed using the following 
conjugated antibodies: TCRαβ (FITC), CD3 (PerCP or APC-Cy7), CD4 (PerCP), CD8α (PerCP), 
CD8β (PE or APC), CD16 (FITC), CD28 (APC or PE-Cy7), CD45RA (FITC) and CD45RO 
(FITC) (BD Biosciences), CMVpp65495-503 pentamer (PE or APC; ProImmune) and TL tetramer 
(PE).  PBMC were pre-incubated with unlabeled anti-CD8α (clone SK1; 2.5 µg/mL; BD 
Biosciences) or anti-CD8β (polyclonal; 100 µg/mL; Abcam or clone 2ST8.5H7; 25 µg/mL; BD 
Biosciences) for 15 min at room temperature.  After a washing step with PBS, TL tetramer (1:100) 
was incubated for 10 min at room temperature. Thereafter, PBMC were co-stained with the 
relevant antibodies for 30 min at 4-8°C.  Plasma CMV IgG titers were analyzed by ELISA using 
Enzygnost® (Dade Behring). All the stained cells were analyzed on a FACSCalibur or FACSCanto 
II flow cytometer (Becton Dickinson) and FlowJo software (Three Star) or FACSDiva® Software 
(BD Biosciences). 
 
In vivo cytotoxicity assays. In vivo cytolytic activity was determined using B6 splenocytes 
differentially labeled with CFSE.  The cells highly labeled (CFSEhigh) were used as target cells and 
pulsed with OVA257-264 (0.5 µg/ml; 90 min at 37°C, 5% CO2), whereas CFSElow labeled cells were 
pulsed with a negative control peptide, TRP-2180-188 (0.5 µg/ml).  Peptide-pulsed target cells were 
extensively washed to remove free peptide and then co-injected intravenously in a 1:1 ratio to 
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recipient mice.  Sixteen hours later, spleens were removed and the ratio of CFSElow/CFSEhigh cells 
was determined by flow cytometry. 
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FIGURE LEGENDS 
Figure 1: TL negatively affects memory generation of CD8αβ+ T cells. (a) WT or TL-/- mice 
were orally infected with 1 × 109 ActA- Lm-OVA. 30 days p.i., splenocytes (SPL) and IEL were 
isolated for IFN-γ intracellular staining after ex vivo re-stimulation with OVA257-264 peptide. Graph 
depicts pooled data ± s.e.m.. (b) 5 × 104 naïve Ly5.1+ CD8+ OT-I cells were adoptively transferred 
into WT or TL-/- recipients. One day after transfer, mice were orally infected with 1 × 109 ActA- 
Lm-OVA. Donor OT-I cells were tracked in the spleen and IEL 2 months p.i. Graph depicts pooled 
data ± s.e.m.. (c) 1 × 106 naïve Ly5.1+ OT-I cells were transferred into WT or TL-Tg recipients. 
One day after transfer, mice were orally infected with 1 × 109 ActA- Lm-OVA. The donor OT-I 
cells in the spleens and IEL were tracked two months p.i. Graph depicts pooled data ± s.e.m.. (d) 5 
× 104 Ly5.1+ naïve OT-I cells were transferred into C57BL/6 mice which were subsequently 
immunized i.v. with 5 × 105 OVAp-loaded DCs generated from bone marrow cells (BMDC) of 
WT or TL-Tg mice (top).  Alternatively, OT-I cells were primed in vitro with TL negative APC or 
APC transfected with TL and then transferred to B6 recipients (bottom).  Memory OT-I cells in the 
spleen were analyzed 2 months after DC immunization or after transfer of in vitro activated OT-I 
cells. Graph depicts pooled data ± s.e.m.. (e) Migratory mLN DCs express a high level of TL. 
Spleen or mLN DC were sorted based on the CD11c and MHC II expression and assessed for TL 
expression by flow cytometry. Data are representative from three independent experiments. (f) 
Freshly isolated SPL or mLN DC were activated with CpG for 1 d and then analyzed for TL 
expression. * P < 0.05, ** P < 0.01, *** P < 0.001 (unpaired t-test). 
 
Figure 2: TL mediates death of activated CD8αβ+ T cells. (a) 1 × 106 naïve Ly5.1+ OT-I cells 
were transferred into WT or TL-Tg recipients and the donor cells in the spleens were tracked one 
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month after transfer (top, n = 5 per group). 1 × 106 in vitro activated Ly5.1+ OT-I cells were 
transferred into WT or TL-Tg recipients and the donor cells in the spleen were tracked one month 
after transfer (bottom, n = 8 per group). (b) Naïve CD8 T cells sorted from WT, FasLgld or Faslpr 
mice were stimulated in vitro by anti-CD3/-CD28 beads for 3 d. 0.5 × 106 activated CD8 T cells 
were transferred into Ly5.1+ WT or TL-Tg recipients and the donor cells in the spleens were 
tracked 1 month after transfer.  Representative data are shown of four mice analyzed in each 
group. Two independent experiments were performed in each case.  
 
Figure 3: Activation-induced CD8αα  rescues CD8αβ  primary effector T cells from TICD. 
(a) 2 × 105 CFSE-labeled naïve E8I-/- OT-I cells were cultured with 4 × 104 OVAp-pulsed DCs 
from SPL or mLN of WT or TL-/- mice that were previously orally infected with ActA- Lm-OVA. 
After 2 d culture, OT-I cells were harvested and analyzed for cell death by Annexin V staining. 
Data are representative of three independent experiments. (b) 5 × 104 naïve Ly5.2+ WT or Ly5.2+ 
E8I-/- OT-I cells were adoptively transferred into Ly5.1 recipient mice. 1 d after transfer, mice were 
orally infected with 1 × 109 ActA- Lm-OVA. Donor OT-I cells were tracked in the spleen and IEL, 
2 months p.i.. Graph depicts pooled data ± s.e.m.. (c) 5 × 104 naïve Ly5.2+ WT or Ly5.2+ E8I-/- OT-
I cells were adoptively transferred into Ly5.1 recipient mice. 1 d after transfer, mice were 
intravenously infected with 2.5 × 105 ActA- Lm-OVA. Donor OT-I cells were tracked in the spleen 
and IEL, 2 months p.i.. Graph depicts pooled data ± s.e.m.. (d) As described in (b) and (c), CD8β 
expression was measured on effector WT OT-I or E8I-/- OT-I cells 7 days post oral infection (left 
panel) or i.v. infection (right panel). (e) As described in (c), CD8β expression was measured on 
memory WT OT-I or E8I-/- OT-I cells 2 m post i.v. infection in the spleen and IEL (f, g) 5 × 104 
naïve Ly5.1+Ly5.2+ WT OT-I and 5 × 104 naïve Ly5.2+ E8I-/- OT-I cells were co-transferred into 
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Ly5.1+ WT or Ly5.1+ TL-/- mice.  One day after transfer, the mice were orally infected with 1 × 109 
ActA- Lm-OVA. Two months p.i., memory OT-I cells were tracked in the spleen and IEL. (f) 
Graph depicts pooled data ± s.e.m. (n = 5 per group).  (g) Staining for CD8αα expression, using 
TL-tetramers, on gated memory WT OT-I cells in IEL of WT or TL-/- recipient mice 2m p.i. 
Representative of at least two independent experiments. 
 
Figure 4: CD8αα  expression correlates with the intensity of TCR activation. (a) Total 
splenocytes were cultured in the presence of graded concentration of soluble anti-CD3 and anti-
CD28 antibodies. CD8αα expression, as measured by TL tetramer staining, was analyzed 3 d after 
in vitro culture. Representative data on gated CD8+ T cells are shown. Three independent 
experiments were performed. (b) Naïve OT-I cells were cultured with artificial APC (MEC.B7) in 
the presence of graded concentration of OVA257-264 SIINFEKL (N4) or altered peptide ligands 
(Q4R7 and Q4). CD8αα expression was detected 2 d after in vitro culture. Three independent 
experiments were performed. (c) 100,000 or 1,000 sorted naïve Ly5.1+ CD8+ OT-I cells were 
transferred into B6 recipient mice. 1 d after transfer, mice were orally infected with 1 × 109 ActA- 
Lm-OVA. 7 d p.i., CD8αα expression was analyzed on Ly5.1+ CD8+ OT-I cells from the spleen 
and  IEL (n = 4 mice per group). (d) 5 × 104 naïve Ly5.1+ CD8+ OT-I cells were transferred into 
WT recipient mice. 1 d after transfer, mice were orally infected with 2 × 108 WT Lm-Q4OVA or 
Lm-N4OVA. 7 d p.i., CD8αα expression was analyzed on donor OT-I cells from the spleen and  
IEL (n = 5 mice per group).  
 
Figure 5: CD8αα  expression marks effector memory CD8αβ  T cells in humans. (a) 
Expression of CD8αα on polyclonal human naive (TN; CCR7+CD45RA+), recently activated 
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effector-memory (TEMRA; CCR7–CD45RA+), effector-memory (TEM; CCR7–CD45RA–) and 
central-memory (TCM; CCR7+CD45RA–) CD8+ T cells was measured by TL-tetramer staining. The 
numbers indicate the percentage of TL-tetramerhi cells. Graph depicts pooled data ± s.e.m. on 
percentage of CD8αα expression on human CD8+ T cells (n = 9). *** P < 0.001 (unpaired t-test). 
(b) TL-tetramer staining of human TEMRA CD8+ T cells is blocked by anti-CD8α but not anti-
CD8β antibody. Data are representative of two independent experiments. (c) CMVpp65-specific 
CD8+ T cells display a TEM/TEMRA phenotype and persist at high frequency in humans. Data from 
two representative donors from a total of six persons are shown. The TL-tetramer staining was 
absent on naive CD8+ T cells and was blocked by an anti-CD8α antibody. 
 
Figure 6: Retinoic acid promotes the affinity-based accumulation of CD8αα+CD8αβ  T cells 
in the intestine. (a) OT-I cells were stimulated by OVAp-loaded DCs from SPL or mLN of WT 
mice with or without 100 nM RA (dot plots) or with LE135 (histogram) in vitro for 3 d and 
CD8αα expression was analyzed. Data are representative of five independent experiments. (b,c) 
OT-I cells were stimulated by SPL or mLN DCs pulsed with OVAp (high, 1 nM; low, 0.01 nM) in 
the presence or absence of 100 nM RA (b) or 5 ng/ml TGF-β (c) in vitro for 3 d and CD8αα 
expression was analyzed. Data are representative of more than five independent experiments. (d,e) 
0.5 × 106 CD8+ OT-I cells isolated from naïve Ly5.1+ OT-I+ Rag-/- mice were adoptively 
transferred into B6 recipient mice.  1 d after transfer, mice were orally infected by 0.5 × 109 ActA- 
Lm-OVA. CD8αα expression was measured on gated donor OT-I cells from the SPL, mLN, PP 
and IEL, 5 d p.i. (d). CD8αα and CD103 expression is shown on gated donor OT-I cells from the 
spleen and IEL on days 12, 21 and 75 p.i. (e). Representative data from two to three mice per 
group are shown. At least three independent experiments were performed. 
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Figure 7:  Constitutive expression of TL on intestinal epithelial cells mediates selection of 
mature memory CD8αβ  T cells. (a,b) Naïve Ly5.1+ CD8+OT-I cells were cultured in the 
presence of APC (MEC.B7.SigOVA). After 2 days’ culture, CD8ααhi and CD8ααlo/- OT-I cells 
were sorted and cultured for 3 more days in vitro. Then 0.5 × 106 CD8ααhi or CD8ααlo/- cells were 
adoptively transferred into B6 recipients. One month after transfer, mice were orally infected with 
5 × 108 ActA- Lm-OVA. Donor Ly5.1+ OT-I cells were tracked in the spleen and IEL 3 d (a) and 5 
d (b) p.i.. Representative data from 3-4 mice in each group are shown. At least five independent 
experiments were performed. (c) As shown in (a), secondary OT-I memory cells were assessed in 
the IEL 45 d p.i.. Representative data from three to four mice in each group are shown. At least 
three independent experiments were performed. (d) Sorted in vitro activated Ly5.1+ CD8ααlo/- OT-
I cells were cultured for 3 d and 0.5 × 106 primary effector cells were transferred into WT or TL-/- 
recipients. One month after transfer, mice were orally infected with 5 × 108 ActA- Lm-OVA. 4 
months p.i., memory OT-I cells were tracked in the spleens and IEL. Pooled data ± s.e.m. are 
shown. At least two independent experiments were performed. (e, f) 5 × 104 naïve CD8+ OT-I cells 
were transferred into Ly5.1+ WT or Ly5.1+ TL-/- recipient mice. 1 d after transfer, mice were orally 
infected with Lm-Q4OVA. Effector OT-I cells in the peripheral blood (7 d p.i.) and memory OT-I 
cells (2 m p.i.) in the spleen and IEL were analyzed. Pooled data ± s.e.m. are shown. (g, h) 5 × 104 
naïve CD8+ OT-I cells were transferred into Ly5.1+ WT or Ly5.1+ TL-/- recipient mice. 1 d after 
transfer, mice were intravenously infected with Lm-Q4OVA. Effector OT-I cells in the peripheral 
blood (7 d p.i.) and memory OT-I cells (2 m p.i.) in the spleen and IEL were analyzed. Pooled data 
± s.e.m. are shown. At least three independent experiments were performed. (i) Ly5.1 mice 
adoptively transferred with 5 × 104 naïve WT or E8I-/- OT-I cells were orally immunized with 1 × 
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109 ActA- Lm-OVA. Two months after immunization, mice were re-challenged orally with 1 × 
1010 WT Lm-OVA. Bacterial loads in the livers were assessed day 3 p.i.. Pooled data ± s.e.m. are 
shown (n = 6). Representative data are shown of three independent experiments. * P < 0.05; ns: no 
significant difference (unpaired t-test). 
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Supplementary Figure 1. TL deletes activated CD8αβ+ T cells. 1 × 106 naïve Ly5.1+ OT-I cells 
were transferred into WT or TL-Tg recipients. One day after transfer, mice were orally infected 
with 1 × 109 ActA- Lm-OVA. Memory CD8+ OT-I cells in the livers were analyzed 2 month p.i.. 
Graph depicts pooled data ± s.e.m.. *** P < 0.001 (unpaired t-test).  
 
Supplementary Figure 2. MHC class IIhi, CD11c+ MLN DC have the phenotype of CCR7+ 
CD103+ migratory DC. (a) mLN contain a distinct MHC class IIhi DC subset that is absent in the 
spleen (dot plots). Surface expression of CCR7 and CD103 were analyzed on CD11c+MHC II+ 
DCs from SPL and CD11c+MHC IIhi or CD11c+MHC IIint DCs from mLN (histograms). Data are 
representative from at least three independent experiments. (b) Spleen or mLN DCs were sorted 
based on the CD11c and MHC II expression and used for mRNA quantification for TL expression 
by qRT-PCR. Data are representative from three independent experiments. 
 
Supplementary Figure 3. Affinity-based selective programming of memory precursor cells does 
not require IL-7R signals. (a) Naïve CD8+ OT-I cells were cultured in the presence of APC 
(MEC.B7.SigOVA). CD8αα and IL-7Rα expression on OT-I cells was determined by flow 
cytometry at different time points. (b) 1 × 104 naïve CD8+ WT OT-I cells or IL-7Rα449F OT-I cells 
were adoptively transferred into Ly5.1 WT recipient mice. 1 d after transfer, mice were orally 
infected with 1 × 109 ActA- Lm-OVA. Donor OT-I cells were tracked in the spleens and IEL 2 
months p.i.. At least three independent experiments were performed. 
 
 Supplementary Figure 4. Expression of CD8α and CD8β on human CD8+ T cell subsets. The bar 
graphs show the relative percentage of CD8α and CD8β mean fluorescence intensity (MFI) in 
human CD8+T cell subsets (n = 9). ** P < 0.01 (unpaired t-test). 
 
Supplementary Figure 5. Characterization of in vitro activated CD8ααhi and CD8ααlo/- CD8αβ+ 
T cells. (a) Naïve Ly5.1+ CD8+ OT-I cells were cultured in the presence of APC 
(MEC.B7.SigOVA). After two days’ culture, CD8ααhi and CD8ααlo/- OT-I cells were sorted and 
cultured for 3 more days in vitro. Then 0.5 × 106 CD8ααhi or CD8ααlo/- were adoptively 
transferred into B6 recipients. 3 d after transfer, effector OT-I cell were tracked in the spleen and 
IEL. (b) Sorted CD8ααhi and CD8ααlo/- OT-I cells were directly stimulated with OVA257-264 
peptide for 5 h and intracellular staining for IFN-γ was performed. (c) 3 d after transfer of 
CD8ααhi or CD8ααlo/-, in vivo cytotoxicity assay was performed in recipient mice. B6 splenocytes 
labeled as CFSEhi and pulsed with OVA257-264 peptide were used as target cells and splenocytes 
labeled as CFSElow and pulsed with the control peptide were used as control target cells. Data are 
representative from three independent experiments. 
 
Supplementary Figure 6. Proposed model for the roles of TL and CD8αα on selection of 
memory CD8αβ T cells. CD8αα expression is selectively induced on high affinity/avidity primary 
effector CD8αβ+ T cells and further enhanced by RA released by mucosal migratory (CCR7+) DC, 
which also promote gut-tropism (α4β7+CCR9+) of the effector T cells. Activated migratory DC 
express the CD8αα high affinity ligand, TL, which when interacting with CD8αβ on activated T 
cells leads to TICD. High affinity primary effector cells that induce CD8αα, escape TICD by 
sequestering TL away from CD8αβ via CD8αα leading to affinity-based selective survival. TL 
 constitutively expressed on the intestinal epithelial cells (IEC) mediates affinity maturation of the 
mucosal TEM and eliminates low affinity/avidity primary and secondary effector cells that home to 
the gut and fail to induce CD8αα. 
 
 







